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Abstract 
Introduction: High rates of chronic non-cancer pain (CNCP), concerns about adverse effects including 
dependence among those prescribed potent pain medicines, the recent evidence supporting active rather 
than passive management strategies and a lack of funding for holistic programme have resulted in 
challenges around decision making for treatment among clinicians and their patients. Discrete choice 
experiments (DCEs) are one way of assessing and valuing treatment preferences. Here, we outline a 
protocol for a study that assesses patient preferences for CNCP treatment. 
Methods and analysis: A final list of attributes (and their levels) for the DCE was generated using a 
detailed iterative process. This included a literature review, a focus group and individual interviews with 
those with CNCP and clinicians who treat people with CNCP. From this process a list of attributes was 
obtained. Following a review by study investigators including pain and addiction specialists, pharmacists 
and epidemiologists, the final list of attributes was selected (number of medications, risk of addiction, 
side effects, pain interference, activity goals, source of information on pain, provider of pain care and out-
of-pocket costs). Specialised software was used to construct an experimental design for the survey. The 
survey will be administered to two groups of participants, those from a longitudinal cohort of patients 
receiving opioids for CNCP and a convenience sample of patients recruited through Australia's leading 
pain advocacy body (Painaustralia) and their social media and website. The data from the two participant 
groups will be initially analysed separately, as their demographic and clinical characteristics may differ 
substantially (in terms of age, duration of pain and current treatment modality). Mixed logit and latent 
class analysis will be used to explore heterogeneity of responses. 
Ethics and dissemination: Ethics approval was obtained from the University of New South Wales Sydney 
Human Ethics committee HC16511 (for the focus group discussions, the one-on-one interviews and 
online survey) and HC16916 (for the cohort). A lay summary will be made available on the National Drug 
and Alcohol Research Centre website and Painaustralia's website. Peer review papers will be submitted, 
and it is expected the results will be presented at relevant pain management conferences nationally and 
internationally. These results will also be used to improve understanding of treatment goals between 
clinicians and those with CNCP. 
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Strengths and limitations of this study
 ► This discrete choice experiment (DCE) will elucidate 
how people with chronic non-cancer pain (CNCP) 
value different treatments that include both medi-
cines and holistic goals of pain management.
 ► Our DCE will be conducted in two samples: an al-
ready recruited diverse cohort of people with CNCP 
who have been prescribed opioids and a novel group 
of people with CNCP who may not have been pre-
scribed opioids, recruited via social media.
 ► The samples will include the most common pain 
conditions such as chronic back and neck problems, 
arthritis and migraines.
 ► The study will estimate marginal willingness to pay 
for changes in number of medicines, level of pain 
interference, risk of addiction and preference of ser-
vice provider.
 ► The preference DCE surveys will be undertaken in 
Australia, which could affect generalisability to other 
settings.
AbStrACt
Introduction High rates of chronic non-cancer pain 
(CNCP), concerns about adverse effects including 
dependence among those prescribed potent pain 
medicines, the recent evidence supporting active rather 
than passive management strategies and a lack of funding 
for holistic programme have resulted in challenges around 
decision making for treatment among clinicians and their 
patients. Discrete choice experiments (DCEs) are one way 
of assessing and valuing treatment preferences. Here, 
we outline a protocol for a study that assesses patient 
preferences for CNCP treatment.
Methods and analysis A final list of attributes (and 
their levels) for the DCE was generated using a detailed 
iterative process. This included a literature review, a 
focus group and individual interviews with those with 
CNCP and clinicians who treat people with CNCP. From 
this process a list of attributes was obtained. Following a 
review by study investigators including pain and addiction 
specialists, pharmacists and epidemiologists, the final 
list of attributes was selected (number of medications, 
risk of addiction, side effects, pain interference, activity 
goals, source of information on pain, provider of pain care 
and out-of-pocket costs). Specialised software was used 
to construct an experimental design for the survey. The 
survey will be administered to two groups of participants, 
those from a longitudinal cohort of patients receiving 
opioids for CNCP and a convenience sample of patients 
recruited through Australia’s leading pain advocacy body 
(Painaustralia) and their social media and website. The 
data from the two participant groups will be initially 
analysed separately, as their demographic and clinical 
characteristics may differ substantially (in terms of age, 
duration of pain and current treatment modality). Mixed 
logit and latent class analysis will be used to explore 
heterogeneity of responses.
Ethics and dissemination Ethics approval was 
obtained from the University of New South Wales Sydney 
Human Ethics committee HC16511 (for the focus group 
discussions, the one-on-one interviews and online survey) 
and HC16916 (for the cohort). A lay summary will be 
made available on the National Drug and Alcohol Research 
Centre website and Painaustralia’s website. Peer review 
papers will be submitted, and it is expected the results will 
be presented at relevant pain management conferences 
nationally and internationally. These results will also 
be used to improve understanding of treatment goals 
between clinicians and those with CNCP.
IntroduCtIon
These are challenging times for both people 
with chronic non-cancer pain (CNCP) and 
those to whom they turn for treatment. 
Despite a significant increase in opioids being 
prescribed for CNCP in countries such as the 
USA, Canada and Australia1–3 there is insuffi-
cient evidence on the long-term effectiveness 
of use.4
Accompanying the increase in opioid 
prescribing there has been a concurrent 
increase in harms, with more than 64 000 
opioid overdoses in the USA,5 1300 in 
Australia6 in 2016 and 8440 in Europe.7 
Responses to minimise harms associated with 
pharmaceutical opioids include increased 
regulatory controls such as prescription 
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monitoring programme and limiting access to over-the-
counter codeine in Canada, Australia and the USA.8 
Other strategies have focused on improved clinical prac-
tice, including limiting maximum doses and prescriber 
education.9 However, taken together with busy general 
practitioners, a shortage of pain and addiction specialists, 
fear of addiction and the lack of accessible and afford-
able alternatives for pain management this has led to 
increased anxiety among many with CNCP.10
With chronic pain reported by approximately one-third 
of the US population11 and 39% percent of a represen-
tative Australian sample,12 and potential rates of depen-
dence varying between 1% and 24%13 among those who 
are prescribed potent analgesic medicines, this represents 
a sizeable challenge.
The benefits and harms of opioids for CNCP are 
complex and contextual, and include factors such as age, 
co-morbidities, health status, type and duration of pain, 
concurrent medicines, patients’ ability and willingness 
to self-manage. Under-treated CNCP adversely affects 
patients’ well-being,10 but there are few data to inform 
the range of treatment choices available, maximise treat-
ment outcomes and patient adherence and minimise 
unintended consequences. In addition, prescribing deci-
sions and patients’ expectations are complicated by the 
common side effects from many medicines used in CNCP, 
the lack of long-term evidence on efficacy,14–17 the devel-
opment of tolerance, fears of dependence and lack of 
funding for non-drug-based treatment options.
Recent evidence suggests that active rather than passive 
management strategies may ‘retrain the brain’ to reduce 
pain,18 and that a multidisciplinary approach is likely to 
produce the most optimal outcomes, but the cost and 
availability of alternative treatments may affect patients’ 
treatment choices. In addition, cognitive behavioural 
therapy has been found to help patients modify situa-
tional factors and multi-modal therapies that combine 
exercise and related therapies with psychologically based 
approaches also help reduce pain and improve function 
more effectively than single modalities.19–21
Preferences of clinicians and patients can impact 
prescribing patterns, uptake of interventions and treat-
ment adherence, thus affecting the effectiveness of pain 
management.22 It is important to understand why some 
people with CNCP resort to treatments that are expen-
sive or without evidence of efficacy; and alternatively, 
why some stay on opioids long-term when not experi-
encing clinical benefit. For example, 34% of a cohort 
of CNCP participants reported that there had been no 
clinically significant change in their activity limitations, 
symptoms, emotions and overall quality of life since 
starting opioids.23 Significant proportions of the cohort 
were using complementary or alternative interventions 
for their pain which have limited or no evidence of effi-
cacy in chronic pain.23 24 In addition, they often report 
that attending physiotherapy, specialised exercise classes 
or psychotherapy was often prohibitively expensive and 
unfunded whereas medicines and general practitioner 
(GP) visits are at least partially covered by the Australian 
Medicare and Pharmaceutical Benefits Schemes.
The discrete choice experiment (DCE) method-
ology allows for the identification of the preferences for 
various treatment options and potential trade-offs that 
individuals are willing to make. Moreover, DCEs have 
been widely used in the health literature to elicit pref-
erences from patient groups on health and non-health 
outcomes.25 26 Studies that have utilised the DCE meth-
odology to examine patient preferences for managing 
CNCP have focused specifically on toleration of the 
adverse effects of nonselective nonsteroidal anti-inflam-
atory drugs (NSAIDs) and selective COX-2 (cyclo-oxy-
genase) inhibitors,27 management of neuropathic pain,28 
surgical or non-surgical approaches for low back pain29 
; and acupuncture or infra-red treatments for low back 
pain.30 These studies have often been limited to specific 
treatments27–30 and to limited conditions.29 30 Here we 
outline a study protocol to elicit patient preferences for 
broader approaches to treatment for CNCP through use 
of a DCE by extending the range of attributes to encom-
pass a wider range of treatment alternatives including 
holistic goals of pain management.
AIMS
The aims of this study are to identify and value the factors 
that influence important treatment decisions among 
people living with CNCP, so we can better understand the 
choices they make. Specifically, we will assess:
1. Preferences for medicines.
2. Impact on choice of potential side effects including 
the possibility of addiction.
3. Willingness to pay (WTP) out of pocket for preferred 
options, and the extent to which costs may be a barrier.
4. The extent to which having input into treatment is im-
portant.
5. The degree to which pain interference is tolerated.
MEthodS And AnAlySIS
overview of the dCE
DCEs are a method of eliciting and quantifying prefer-
ences and exploring trade-offs between the attributes 
(characteristics) of a treatment (or a good or service). 
Attribute-based DCEs permit the exploration of pref-
erences for treatment options while varying the levels 
of each attribute.26 31 32 DCEs are based on Lancaster’s 
economic theory of value (1966, 1971) and presume that 
individuals derive utility (or well-being) not from the 
good itself but rather from the attributes of that good.33 34 
They rely on an individual’s knowledge or perceptions of 
their own preferences, and on their ability to make trade-
offs between alternatives in the presence of constraints 
such as money, time, availability and so on.
A DCE provides respondents with several hypothetical 
but reasonable choice sets. Each choice set consists of at 
least two alternatives that comprise a set of attributes each 
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with various levels. Respondents are then asked to choose 
their preferred alternative in each choice set.33 In making 
a choice, the respondent identifies the alternative that 
yields the highest utility to them. The attributes and their 
levels are important, as they drive decision making. When 
respondents make a choice, they make trade-offs between 
the levels of the various attributes that can then be anal-
ysed with logistic regressions. When a cost attribute is 
included, it is possible to indirectly estimate WTP values 
for particular attributes of treatment.35–38 The dependent 
variable in the logistic regression represents the proba-
bility of choosing one alternative with specific attributes 
and levels over another. The independent variables are 
the attributes and their levels. It is feasible to account 
for heterogeneity through the use of covariates in mixed 
logit (MXL) or latent class (LC) models.39 40
Theory
Consumer theory assumes deterministic behaviour, but 
choice theory asserts that individual behaviour is intrin-
sically probabilistic (random). Individuals have a concept 
of the value (indirect utility) for each choice, but the 
researcher does not know all the factors that might affect 
that choice. The utility estimate consists of the knowable 
part and the random or unknowable parts. The random 
part may be due to unobserved attributes, unobserved 
preference variation, specification or measurement error, 
or inter-individual differences in utility as a result of varia-
tion in tastes.33 41 The utility function in the context of the 
DCE can be presented as follows:
 Uij = Vij+ϵij,j=1.....,J  (1)
where individual i will choose alternative j if, and only 
if, that alternative maximises their utility among all J alter-
natives. The utility (U) for individual i is conditional on 
choice j and decomposed into explainable or systematic 
Vij and non-explainable or random component εij. Vij can 
be further broken down into Xjk, a vector of attributes of 
the treatment, and Z, a vector of N characteristics of the 
individual i, and β and γ are the respective coefficients 
to be estimated for K attributes, with γn coefficients indi-
cating the impact that the personal characteristics have 
on choice.42
 
Vij =
K∑
k=1
βkXjk +
N∑
n=1
γnZin
 
(2)
where yij is equal to 1 if alternative j is chosen, and 0 
otherwise and 1 is the choice if and only if
Vij + εij > Vim + εim for all j ≠ m which rearranges to
Vij - Vim > εim- εij.
Utilities are not observed, but by documenting the 
choices made, utilities can be estimated.43 In addition (εim 
− εij) is not observed directly and so it is only possible to 
make observations up to a probability of occurrence with 
some distribution or density function. It is the choice of 
this distribution that affects interpretation of the proba-
bilities.33 Different density functions for the unobserved 
part of the utility εij lead to different families of probabi-
listic discrete choice models.
Undertaking a DCE requires several steps including 
the selection of the relevant attributes and their 
levels, obtaining a feasible design for the DCE survey, 
constructing and administering the survey and deter-
mining the best-fitting model.
Patient and public involvement
The final survey tool (the DCE), including the framing 
of the question, was developed after a focus group discus-
sion and multiple one-on-one discussions with persons 
who self-report as having CNCP. They were recruited 
from members of Painaustralia. Painaustralia is Australia’s 
leading pain advocacy body representing the interests of a 
membership that includes health, medical, research and 
consumer organisations it works to improve the quality 
of life of people living with pain and to facilitate imple-
mentation of the National Pain Strategy Australia-wide. 
As further described below, the important constructs 
from this qualitative work informed the choice of attri-
butes, levels and the final question. A lay summary of the 
findings will be made available on the National Drug and 
Alcohol Research Centre (NDARC) website and Painaus-
tralia’s website.
Determining the attributes and levels for the DCE
The selection of attributes and their levels is a key step. 
There is a need to balance the number of attributes to 
adequately describe the good or service of interest; spec-
ifying too many attributes may hinder the respondents’ 
decision making. The number of attributes will vary with 
the complexity of the good being considered, but typically 
studies include four to eight attributes. Undertaking qual-
itative work to inform the selecting and framing improves 
the relevance and applicability of the findings.44 45
Focus groups and telephone interviews with people living with 
CNCP
As a first step in this study, a literature review was under-
taken to identify the important constructs to explore in 
subsequent focus groups and one-on-one discussions. The 
intent was to recruit 20 to 25 participants to participate in 
focus groups; however, it became apparent this was going 
to be difficult due to health status of participants and loca-
tion. Therefore, one focus group (N=3 participants) and 
13 one-on-one telephone interviews were conducted with 
people who had CNCP, to elicit views on topics such as 
self-management, knowledge of pain mechanisms, brain 
plasticity, relative importance of exercise, medicines, 
choice of treatment provider and barriers and facilitators 
to effective good treatment.
Telephone interviews with clinicians
In addition, interviews were conducted with a range of 
clinicians including pain specialists, general practitioners 
(urban and rural), clinical nurse specialists, physiothera-
pists and addiction specialists (N=8). Clinician interviews 
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Table 1 Final attributes and levels
Attributes Levels
Number of different medications taken on most days for pain 0, 2, 4,6
Known side effects of medications for pain Mild, moderate/severe
Pain interference with daily activities Never; sometimes; most of the time; always
Pain care is managed by GP only; pain specialist; multidisciplinary pain 
management team; myself
Risk of addiction to pain medication Risk of 3 in 100 people or 25 in 100 people who are taking 
strong pain medications*
Activity goals of treatment Able to undertake activities of daily living; do exercises at 
home, including walking, most days; participate in regular 
exercise classes (gym/hydrotherapy classes); practice 
mindfulness regularly
Source of information on pain and pain management None; from a doctor; by reading/online; from a pain 
management course
Out-of-pocket costs per month (ie, for medications, doctor, physio 
or psychologist visits, or other activities you would need to pay for 
to help you manage your pain)
$50, $100, $200 or $300 per month
*Initial choice of four levels decreased to two after pilot study, see below.
GP, general practitioner.
elicited additional information on barriers and facilita-
tors to treatment and views on current modalities of treat-
ment for CNCP.
Determining the list of attributes and levels
The final list of attributes included in the DCE experi-
ment was generated using a detailed iterative process. 
The first phase involved a literature review undertaken by 
MSh to inform the development of list of possible factors 
previously identified as influencing patient choice of 
pain treatments. This list was reviewed and further devel-
oped among the broader pain and opioids in treatment 
(POINT) study investigators that include pain and addic-
tion specialists, pharmacists and epidemiologists.
These attributes developed in the first phase of the 
study became the basis of (a) focus group discussions with 
patients and (b) telephone interviews with clinicians. Two 
authors (MSh and GC) reviewed the recorded transcripts 
separately and independently analysed data thematically. 
Attributes generated at this second phase included the 
following themes: potential side effects; concurrent medi-
cines; necessity to work/care for others; barriers; comple-
mentary medicine; multi-modal therapies; costs; time to 
onset of effect; adherence/compliance; risk of addiction; 
co-morbidities; and self-management.
In the final phase, this broader list was reviewed by the 
broader POINT study investigator team, and a final list of 
attributes (and their levels) was agreed. Attributes (and 
number of levels) selected were number of medications 
(4), risk of addiction (4), side effects (2), pain interfer-
ence (4), activity goals, source of information on pain 
(4), provider of pain care (4) and out-of-pocket costs (4).
Pilot study
The DCE design
Having selected the attributes, levels and number of alter-
natives (2), an experimental design for the survey was 
generated. Given the number of attributes and levels, a 
full factorial design including all possible combinations 
of attributes and their levels was not feasible. Therefore, 
a D-efficient experimental design that maximised model 
statistical efficiency by minimising the parameter stan-
dard errors was generated using Ngene.46 The statistical 
efficiency of the design is improved if some prior infor-
mation about these parameters is available. This can be 
coefficients from previous analysis or expert opinion.43 46 
In the design for the pilot study, the prior coefficients 
were set to zero.
Pilot-testing attributes and levels
A pilot study was conducted among 33 people living with 
CNCP and who had been prescribed opioids. These data 
were used to refine the final list of attributes and levels. 
Specifically, the number of levels for the attribute ‘risk of 
addiction to pain medicines’ was decreased from 4 to 2 
levels (the two extremes), as respondents did not appear 
to distinguish between the middle two levels. (See table 1 
for final list of attributes and levels). The pilot testing was 
also used assess the ease with which participants could 
complete the experiment: 64% reported that it was easy/
very easy to complete the scenario questions, 27% found 
it difficult and 9% found it very difficult.
Proposed study
Significant coefficients from the pilot study data (n=33) 
were used in the final experimental design. An efficient 
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Table 2 Example of scenario
Treatment A Treatment B
Pain medications per day 2 4
Known side effects of medications Mild Moderate/severe
Pain interference Never Never
Pain care is managed by Myself GP only
Risk of addiction to pain medications 3 in 100 people 25 in 100 people
Activity goals of treatment Do exercises at home, including walking Do exercises at home, including walking
Source of information on pain From my doctor By reading/online
Out-of-pocket costs per month 300 300
My choice is (please choose A or B) □ □
GP, general practitioner.
design of 80 scenarios, with 10 blocks was generated for 
the final design (each participant will be presented with 
one block of eight scenarios). See table 2 for an example 
of a scenario.
Participants and survey procedures
There is no agreement on the correct sample size 
required for a DCE.47 However, research has shown that 
in all DCE studies with efficient designs, model estimate 
precision increases rapidly at sample sizes greater than 
150 and then flattens out at around 300.48 It is also esti-
mated that a minimum sample size of 200 respondents 
per sub-group be used for studies involving an analysis 
of differences between samples.49 The proposed DCE will 
be administered to two groups of participants (see below) 
with the sample size of each group being 200 participants 
or greater. To examine the possibility of different treat-
ment preferences in people living with CNCP we included 
two distinct groups. The POINT cohort consist of partic-
ipants who have been prescribed opioids for CNCP and 
have been on long-term opioids for an average of 7 
years at the time of the current study. The other sample 
includes CNCP recruited online. These participants are 
not necessarily prescribed opioids and we will examine 
the differences in treatment preferences between people 
prescribed and not prescribed opioids for CNCP.
Each participant will be randomly allocated to one of 
10 blocks with each block having eight DCE questions. In 
addition to the DCE questions, a range of demographic 
and covariates (ie, age, gender, education, marital status) 
and clinical characteristics (duration of pain, number 
and type of medicines, pain interference scores) will be 
collected.
Pain and opioids in treatment (POINT) prospective cohort study
The first source includes participants in POINT study, a 
national prospective cohort of 1514 people living with 
CNCP.23 The POINT study, currently in its fifth year, 
recruited participants through community pharmacies 
across Australia. Participants when recruited were: 18 
years or older; living with CNCP (defined as pain lasting 
longer than 3 months); taking prescribed Schedule 8 
opioids (including morphine, oxycodone, buprenor-
phine, methadone and hydromorphone) for CNCP 
for greater than 6 weeks when recruited; competent in 
English; mentally and physically able to participate in 
telephone and self-complete interviews; and did not have 
any serious cognitive impairments, as determined by the 
interviewer at the time of screening. The POINT cohort 
participants are interviewed annually over the phone, 
and the DCE survey will be included as part of the fifth-
year interview. Participants in the POINT cohort study 
will be invited to participate in the survey and reasons for 
not participating will be recorded; the first consecutive 
33 interviews of the fifth-year interview were administered 
the pilot study questionnaire and these participants will 
not complete a second DCE. The DCE will be mailed to 
participants prior to the date of interview along with an 
explanation of the study aims and consent forms. The 
DCE questionnaire will then be completed by the POINT 
interviewers over the phone as part of the regular POINT 
interview schedule. Covariates for the DCE will be drawn 
from baseline data and the most recent interview.
Online survey of people living with CNCP
A second group of respondents will be recruited online 
through Painaustralia, a national peak body and pain 
advocacy organisation, and through social media. This 
group will be asked to complete an identical DCE survey 
online (via Qualtrics, hosted at the University of New 
South Wales (UNSW) Sydney), plus selected demo-
graphic, pain characteristics, type of medicines, questions 
drawn from the POINT survey. Similar to the POINT 
cohort, participants who are eligible for the online survey 
will be aged 18 years or older, reside in Australia and are 
living with CNCP (defined as pain lasting longer than 3 
months). Unlike the POINT cohort, however, the online 
sample will not be required to have been prescribed 
Schedule 8 opioids (although this is not an exclusion in 
the online survey).
Links to the online survey will be posted on the Pain-
australia’s website, the NDARC website, and their asso-
ciated Facebook pages, and twitter feeds. Recruitment 
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will continue for 4 months (or until the current round 
of interviews of the cohort are complete) with the objec-
tive of achieving at least 200 surveys completed online. 
Respondents will be randomly allocated one of the 10 
blocks, and demographic and covariates collected from 
the POINT cohort will match.
data analysis
The data from the two participant groups will be initially 
analysed separately, as their demographic and clinical 
characteristics may differ substantially (in terms of age, 
duration of pain and current treatment modality). The 
analysis of the DCE responses will be analysed using 
Nlogit software.46 Initially a multinomial logit model will 
be used. MXL and LC analysis will be used to explore 
heterogeneity of responses. Number of medicines and 
out-of-pocket costs will be treated as continuous variables; 
all categorical variables will be effects coded which means 
the constant will not be confounded with the grand mean 
and coefficients for base levels can be estimated.50
Tables of coefficients for the levels and covariates will 
be presented with relevant statistical measures including 
pseudo r-squared, log likelihood test and the Akaike 
information criterion (AIC) to test for goodness of fit 
of the model. In addition, the marginal rate of substitu-
tion (the negative ratio between any two estimated coef-
ficients) will be calculated. This will allow policy makers 
and clinicians to understand the relative importance of 
different attributes, and the respondents’ willingness to 
give up some amount of one attribute in order to obtain 
more of another.
Article summary
Strengths and limitations of this study
The DCE approach offers great potential for informing 
clinicians as to patient preferences for pain management. 
Where preferences do not align with current evidence, the 
findings will provide an opportunity to develop strategies 
for improving knowledge. If preferred options are those 
that are known to be effective but also more expensive 
for the patient, the results can be used to inform policy 
makers. However, there are methodological limitations 
that are common to all DCEs. In our study, one challenge 
was to select attributes and levels that both reflect treat-
ment for CNCP and outcomes but result in a practical 
number to include. Our choice to use eight attributes 
likely places higher cognitive demand on respondents but 
we sought to mitigate this by only requiring each person 
to complete eight DCE choices.
Our DCE will be conducted in a large, diverse sample 
of people living with CNCP, including the most common 
pain conditions such as chronic back and neck prob-
lems. This DCE differs from previous studies in that it will 
elucidate how people value different CNCP treatments, 
not just medicines or not just surgery. This study will also 
permit the estimation of the marginal WTP for different 
treatment options and outcomes. Although the marginal 
WTP for preferred attributes will assist policy makers 
generally, some of the results may not be generalisable 
to resource-poor settings or countries without universal 
healthcare systems.
Ethics and dissemination
A lay summary of the findings will be made available on 
the NDARC website and Painaustralia’s website. Peer 
review papers will be submitted, and it is expected the 
results will be presented at relevant pain management 
conferences nationally and internationally. These results 
will also be used to improve understanding of treatment 
goals between clinicians and those with CNCP goals.
Consent
Written consent was obtained from those who attended 
the focus groups and verbal consent was obtained from 
those who volunteered for phone interviews (researchers 
were only aware of first name of telephone participants). 
Consistent with UNSW ethics, for the online DCE survey, 
consent was implicit in the decision to complete the 
survey after reading the participation information sheet. 
For the POINT cohort, consent has previously been 
obtained from participants and the DCE is part of the 
scheduled interview.
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